145. ウエスト症候群
［臨床試験数：39，薬物数：50（DrugBank：13），標的遺伝子数：27，標的パスウェイ数：24］
Searched query = "West syndrome", "Infantile spasm"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2006-000788-27-DE (EUCTR) | 23/09/2010 | 11/06/2010 | International Collaborative Study of a type of epilepsy called Infantile Spasms | International Collaborative Infantile Spasms Study (ICISS) - ICISS | Infantile spasms are a rare severe form of epilepsy affecting approx 1 in 2,250 infants, usually under the age of 1 year. Affected infants have a very abnormal EEG and a poor prognosis for subsequent epilepsy and neuro-development. There is a high risk of underlying neurological disease that independently causes delayed development and other seizure disorders. There is a high risk of a poor outcome even when there is no other detectable underlying neurological disorder.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: SABRIL INN or Proposed INN: Vigabatrin Trade Name: Synacthen Depot INN or Proposed INN: Tetracosactide Acetate Trade Name: Decortin H INN or Proposed INN: Prednisolone | Royal United Hospital Bath NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | 410 | Phase 4 | Australia;Germany;United Kingdom;Switzerland;New Zealand | ||
| 2 | EUCTR2006-000788-27-GB (EUCTR) | 20/04/2006 | 06/03/2006 | International Collaborative Infantile Spasms Study (ICISS) - ICISS | International Collaborative Infantile Spasms Study (ICISS) - ICISS | Infantile spasms are a rare severe form of epilepsy affecting approx 1 in 2,250 infants, usually under the age of 1 year. Affected infants have a very abnormal EEG and a poor prognosis for subsequent epilepsy and neuro-development. There is a high risk of underlying neurological disease that independently causes delayed development and other seizure disorders. There is a high risk of a poor outcome even when there is no other detectable underlying neurological disorder. | Trade Name: SABRIL SACHETS INN or Proposed INN: Vigabatrin Trade Name: SYNACTHEN DEPOT INN or Proposed INN: Tetracosactide Acetate Trade Name: SOLUBLE PREDNISOLONE TABLETS INN or Proposed INN: Prednisolone | Royal United Hospital Bath NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | 410 | Phase 4 | Germany;United Kingdom |